Drug Trial Radar · NCT02434861
An Open Label, Single Dose, Three Part Study to Assess the Effects of Rolapitant (2 mg/mL IV Solution) on the Pharmacokinetics of Digoxin; Sulfasalazine; and the Cooperstown Cocktail (Midazolam, Omeprazole, Warfarin, Caffeine, and Dextromethorphan in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Aug 25, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
May 2015
Primary completion
Jul 2015
Study completion Aug 2015
Sponsor
- Lead sponsor
- Tesaro, Inc.GSK (GSK)
- Sponsor type
- Industry
- First posted
- May 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this Open Label Study is to evaluate effects of Rolapitant IV solution, and its metabolite, on the pharmacokinetics (PK) of the P-gp substrate (digoxin), the BCRP substrate (sulfasalazine), and multiple cytochrome P450 (CYP) probe substrates in a healthy adult population.
Conditions
- Chemotherapy-induced Nausea and Vomiting
Interventions
RolapitantDrug
DigoxinDrug
P-gp substrate
SulfasalazineDrug
BCRP substrate
Cooperstown CocktailDrug
Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
Primary outcomes
What the sponsor says the trial is designed to measure.
- AUC: area under the plasma concentration-time curveTime frame: Predose - up to 120 hours postdose
- Cmax = observed maximum plasma concentrationTime frame: Predose - up to 120 hours postdose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Parexel Early Phase Unit
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.